Altimmune, Inc. presented data on pemvidutide for MASH at EASL Congress 2026, held in Barcelona, led by principal investigator Mazen Noureddin.
4 reports, 3 independent
Updated Jul 5
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Altimmune, Inc. presented data on pemvidutide for MASH at EASL Congress 2026, held in Barcelona, led by principal investigator Mazen Noureddin.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Altimmune, Inc.
American biopharmaceutical company
-
Barcelona
city in Catalonia, Spain
Coverage
Newest first; wire copies grouped- yahoo.com
- manilatimes.net
- manilatimes.net
- ZacksAltimmune Gears Up to Report Q2 Earnings: Here's What to Expect We expect investors to focus on Altimmune’s ALT progress in the studies evaluating its lead pipeline candidate, pemvidutide, when it re